Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. Jan 27, 2022; 13(1): 1-14
Published online Jan 27, 2022. doi: 10.4331/wjbc.v13.i1.1
Published online Jan 27, 2022. doi: 10.4331/wjbc.v13.i1.1
Current understanding of the role of tyrosine kinase 2 signaling in immune responses
Ryuta Muromoto, Tadashi Matsuda, Department of Immunology, Graduate School of Pharma ceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan
Kenji Oritani, Department of Hematology, International University of Health and Welfare, Narita 286-8686, Japan
Author contributions: Muromoto R, Oritani K and Matsuda T participated sufficiently in this work of drafting the article and/or revising the article for the important rational content; all authors gave final approval of the version to be submitted.
Supported by Grant-in-Aid for scientific research from Ministry of Education , Culture, Sports, Science and Technology of Japan, No. 19H03364 and No. 20K07010.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tadashi Matsuda, PhD, Professor, Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku Kita12 Nishi 6, Sapporo 060-0812, Japan. tmatsuda@pharm.hokudai.ac.jp
Received: March 27, 2021
Peer-review started: March 27, 2021
First decision: July 27, 2021
Revised: August 6, 2021
Accepted: December 22, 2021
Article in press: December 22, 2021
Published online: January 27, 2022
Processing time: 301 Days and 5.1 Hours
Peer-review started: March 27, 2021
First decision: July 27, 2021
Revised: August 6, 2021
Accepted: December 22, 2021
Article in press: December 22, 2021
Published online: January 27, 2022
Processing time: 301 Days and 5.1 Hours
Core Tip
Core Tip: Studies on murine tyrosine kinase 2 (Tyk2)-deficient models were reviewed to examine the role of Tyk2 dysregulation in human diseases. Tyk2-deficient mice exhibit reduced responses in several interleukin-12 (IL-12)/Th1- and IL-23/Th17-mediated models of diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases, psoriasis, sarcoidosis, and delayed-type hypersensitivity. These findings demonstrate a broad contribution of Tyk2 to immune responses. Tyk2 represents a candidate for drug development by targeting both the IL-12/Th1 and IL-23/Th17 axes.